Dutogliptin联合非格司亭治疗急性STEMI后早期恢复的2期随机双盲安慰剂对照方案
本研究为2期随机双盲安慰剂对照试验方案,评估Dutogliptin联合非格司亭(G-CSF)在急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入(PCI)后左室射血分数(LV-EF)<45%者的安全性与初步疗效。
要点
- Dutogliptin为新型DPP4抑制剂,可升高SDF-1α促进干细胞归巢。
- 联合非格司亭 mobilization 干细胞,小鼠模型显示改善生存并减小梗死面积。
- 主要初步疗效指标为cMRI检测LV-EF较安慰剂改善>3.8%。
核心结论
- REC-DUT-002试验首次评估Dutogliptin联合G-CSF在STEMI患者中的安全性与初步疗效。
- 结果将为设计足够把握度的心血管结局试验奠定基础。
研究设计与样本
- 2期随机双盲安慰剂对照试验方案。
主要发现
- 小鼠模型显示Dutogliptin联合G-CSF显著改善生存并减小梗死面积。
- 初步疗效以cMRI检测LV-EF较安慰剂改善>3.8%进行分析。
关键数值与推荐
- 入组条件:STEMI、LV-EF<45%、已行PCI。
- 主要初步疗效阈值:cMRI检测LV-EF改善>3.8%(与安慰剂比较)。
临床怎么用
- 该方案尚处于试验阶段,结果未出,暂不能用于临床实践。
- 若验证有效,将为STEMI后再生治疗提供微创药物策略。
局限性
- 原文未报告样本量计算依据、主要终点统计假设及盲法实施细节。
- 初步疗效阈值>3.8%的依据未在摘要中说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regenerative therapies offer new approaches to improve cardiac function after acute ST-elevation myocardial infarction (STEMI). Previous trials using bone marrow cells, selected stem cell populations, or cardiac stem cell progenitors require invasive procedures and had so far inconclusive results. A less invasive approach utilizes granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells to circulating blood and induce neovascularization and differentiation into endothelial cells and cardiomyocytes. Stromal cell-derived factor 1 alpha (SDF-1α) is an important chemokine for initiating stem cell migration and homing to ischemic myocardium. SDF-1α concentrations can be increased by inhibition of CD26/DPP4. Dutogliptin, a novel DPP4 inhibitor, combined with stem cell mobilization using G-CSF significantly improved survival and reduced infarct size in a murine model. METHODS: We test the safety and tolerability and efficacy of dutogliptin in combination with filgrastim (G-CSF) in patients with STEMI (EF < 45%) following percutaneous coronary intervention (PCI). Preliminary efficacy will be analyzed using cardiac magnetic resonance imaging (cMRI) to detect > 3.8% improvement in left ventricular ejection fraction (LV-EF) compared to placebo. One hundred forty subjects will be randomized to filgrastim plus dutogliptin or matching placebos. DISCUSSION: The REC-DUT-002 trial is the first to evaluate dutogliptin in combination with G-CSF in patients with STEMI. Results will lay the foundation for an appropriately powered cardiovascular outcome trial to test the efficacy of this combined pharmacological strategy. TRIAL REGISTRATION: EudraCT no.: 2018-000916-75 . Registered on 7 June 2018. IND number: 123717.
引用
- von Lewinski D, Selvanayagam JB, Schatz RA, et al. "Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial. Trials. 2020. PMID: 32843081. doi:10.1186/s13063-020-04652-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。